HK-listed gold stocks jump as US economic fears boost bullion prices
Jacquelyn Fahey Sandell, Chief Legal Officer at Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. The transaction comes as the stock has declined over 25% in the past week, though InvestingPro analysis suggests the company maintains strong financial health with a current ratio of 8.45x and more cash than debt on its balance sheet. On February 11, Sandell sold 4,358 shares of common stock at an average price of $4.45 per share, resulting in a total transaction value of $19,393.
The sale was conducted under a durable automatic sales instruction letter, intended to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Sandell retains ownership of 81,643 shares in the company. The shares were sold at prices ranging from $4.13 to $5.00.
In other recent news, Voyager Therapeutics has announced a critical shift in its gene therapy program for amyotrophic lateral sclerosis (ALS). The company is exploring alternative payloads for its development candidate VY9323, following data from non-human primate studies that indicated the need for a different payload to meet the desired product profile. This change has resulted in a delay of the investigational new drug (IND) application for VY9323, which was previously expected for mid-2025.
Despite this setback, Voyager Therapeutics’ other gene therapy programs remain unaffected. The company continues to anticipate IND filings in 2025 for gene therapy candidates targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ataxia, in partnership with Neurocrine (NASDAQ:NBIX) Biosciences. Additionally, an IND filing for VY1706, a tau silencing gene therapy program, is expected in 2026.
Financially, Voyager Therapeutics estimates that its current cash reserves, along with expected reimbursements from collaborations and interest income, will sustain its planned operating expenses and capital expenditure requirements into mid-2027. This recent development, however, does not affect the company’s collaborations. Analyst firms H.C. Wainwright and Citi have maintained their positive outlook on Voyager, with H.C. Wainwright confirming a Buy rating and a price target of $30.00, while Citi initiated a Buy rating with a price target set at $12.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.